Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trial sites? How will the testing be tracked? Thanks.
woohoo take that Ben Sharvy..
Just alleviating some of the debilitating symptoms should get it to approval. The method now is ice chips.
I believe you are right that Leo thought with the promising early Brilacidin ABSSSI data the share price would fall into line with uplisting. Now after FDA meeting this month Brilacidin will probably still be the catalyst hopefully next month.
Company Spotlight
3 Innovators Leading the next breakthroughs in Technology.
http://ir.baystreet.ca/article.aspx?id=139&1434607733
New Approach to Alzheimer’s Disease: (Anavex Life Sciences: AVXL)
Dr. Christopher Missling is the CEO and President of Anavex. The biotech company is developing interesting and novel compounds to treat Alzheimer’s disease, CNS diseases and conditions that are of significant unmet medical need. Two decades of health care experience, a MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management underscore Dr. Missling’s science and business acumen.
Missling has amassed a rich pipeline at Anavex, advancing two drug candidates to mid-stage trials. The company is hoping to reduce development risk with its lead drug candidate, Anavex Plus, for Alzheimer’s because it combines Anavex 2-73 with donepezil. Anavex Plus is unique in targeting multiple AD pathways simultaneously at different levels of the disease stage. The company believes Anavex Plus could have commercial appeal due to donepezil, the world’s best selling Alzheimer’s drug marketed by Japan’s Eisai (ESALY) and Pfizer (PFE) as Aricept®, losing patent protection in 2010. Dr. Missling’s resume includes serving as CFO of Curis (CRIS) and CFO at Immunogen (IMGN). He also was in charge of financial planning on all aspects of financial strategy and M&A during his time at Aventis, which eventually became part of what is now Sanofi (SNY) subsequent to a $64 billion merger in 2004.
Durable Alzheimer’s treatments have eluded drug makers for years. The value of an effective therapy was evidenced in the massive initial public offering last week of Axovant Sciences Ltd (AXON), a company with no marketed products, but a heralded Alzheimer’s drug ready to enter a Phase 3 trial.
Conclusion
In today’s environment, successful companies must be able to quickly adapt to changing markets and new technology. These industry leaders have been able to create promising businesses that are capitalizing on new technology, positioning their companies as forerunners in their perspective markets. This should lead to exponential growth, making them companies to watch.
My thoughts exactly. I'm excited to hear outcome of FDA meeting and when Phase3 commences. Should be a great summer.
My thoughts exactly.
Form 8-K out today.
17-Jun-2015
Change in Directors or Principal Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective June 15, 2015 (the "Effective Date" ), the board of directors (the "Board" ) of Anavex Life Sciences Corp., a Nevada corporation (the "Company" ), appointed Steffen Thomas, PhD, to serve as a member of the Board until his successor is duly elected, qualified and seated or until his earlier resignation or removal.
In addition to being a member of the Board, it is anticipated that Dr. Thomas will serve on the Audit Committee, effective as of the Effective Date. As compensation for his services, the Company granted Dr. Thomas options to purchase two hundred thousand (200,000) shares of common stock in the Company, said options to vest annually over a three year period commencing on the first anniversary of the Effective Date.
The Company has not entered into any transactions with Dr. Thomas that would require disclosure pursuant to Item 404(a) of Regulation S-K under the Exchange Act of 1934, as amended.
I agree Brillacidin FDA phase 3 approval will be huge for CTIX and really further validate B-OM as well as the other trials Brillacidin would be used in.
No, the truth is Brillacidin was never delayed. Before formal meeting took place FDA asked for a complete patient study workup which took more time. Perhaps Leo got ahead of himself do to his high confidence. A FDA delay sounds much scarier though huh.
Uplist is a work in progress. Even with the delay, indications show this stock will soon moon shot with or without uplist. Uplist will soon follow I might add.
Nice retrace rally. Expecting more positive trial news soon.
Thanks! btw go pound sand.
There are no guarantees. Didn't you look over the last 10-Q.
Prurisol effective against psoriasis so in theory it could possibly work clearing other Autoimmune diseases.
I have adblockplus for chrome running in the back ground. Works like a charm shooting down ads and popups. adblockplus.org
I believe as in the case of CTIX today that the upcoming developing catalysts will remedy low share price without a need of R/S. We have the goods why give up 50 or 75% of your shares to arrive at the same pps a little while down the road. We are only down by some .40cents to get on the Nasdaq CM. Brillacidin catalyst alone could do this.
Sounds like sage advice.
haha thanks catching for that. Maybe 4:1 in the future.
Leo could announce a 1:4 R/S today and we would be on the Nasdaq next week. I think the cost of a reverse split for the retail investors in the long run would be enormous especially in light of the upcoming catalysts. CTIX has the goods to raise share price soon without doing a R/S.
"The application remains pending". No R/S. Leo knows the upcoming catalysts should soon remedy this low price complication.
"52 percent of phase 3 trials are not approved. We have a long road and anything can happen". as said.
They cast doubt out of fear. It's clear this stock is a sleeping giant. Buying after Qualified Infectious Disease Product (QIDP) designation for Brilacidin will look like childs play against uplisting news with following, FDA Brilacidin phase3, B-OM early indications and Kevetrin progressing to phase2/3.
Wow buyers showed up nice to see the love.
I'm thinking that the full p21 report in a scientific journal would be our ticket to ride.
Leo reported in the 10Q that "the Company is saving the full p21 results for an appropriate scientific venue". Would any poster have an idea what the scientific venue would be?
Also great validation in May22 PR: "We could have concluded the trial with the completion of the target enrollment, but we have a novel drug delivering compelling data that we want to push to the limit to best direct the scope of future studies".
"With 40 patients enrolled, Cellceutix feels that it has more than ample data supporting the safety of Kevetrin as well as evidence of possible therapeutic benefits. As such, the Company is moving forward with confidence in preparing documentation for a meeting with the Food and Drug Administration seeking to initiate a Phase 2/3 trial of Kevetrin against a specific type of cancer".
I read the positive posts as validation of the science so far. The leadership PR'd positive Phase2A to date and that's worth positive reviews. IMO to post a negative counter behind a positive report as if looking out for investors is a ruse.
Living on Leo time...Don't worry Bobby we'll get there maybe later then sooner maybe even a little grayer but we'll get there.
Big uplisting news tomorrow?
haha, thanks 123tom.
haha, thanks 123tom.
Thanks Drano. Yes I saw a few familiar names looks like good company. AVXL looks like the real deal being fully reporting.
Thanks Drano. Yes I saw a few familiar names looks like good company. AVXL looks like the real deal being fully reporting.
Hello board. Promising Alzheimer’s data. Bought a position this morning.
Reporting Increased Enrollment in Cellceutix's Clinical Trial of New Cancer Drug and also seeking Phase 2/3 Trial of a specific cancer in the same PR is huge news. The potential to see more then one phase 2/3 trials come out of this phase 1 is possible. This is another huge development for this little biotech. Congratulations to Leo and company and to all us longs.
Yes and I firmly believe they are. This thing will come together and right itself soon I hope.
Cellceutix has a magical pipeline and could have the tiger by the tail if management gets it's act together and just stop the undue over promising, post the milestones when you have one not that your waiting for one. Now we wait for the next promise to come to fruition while the stock price gets pummeled by uncertainty. Brilacidin Phase3 and a surprise partnership could be our salvation I think. The QIDP Designation was a total surprise and sent ctix into new highs. Nice surprise that caught many by surprise. My thoughts have at it.
Are they listed on the Nasdaq?
Agree these conferences while good for showing progression to others in the field do very little for share price if any. But what this Kevetrin poster can do is bolster shareholder confidence. It's what comes out of the event is whats important.
Upcoming material events is what brings in new investors and value. Next comprehensive update to include: Nasdaq uplisting, Increased biomarker p21 measurment at the higher dose showing reactivation of p53(hoping for more patient responses).